USFDA issues 6 observations to Aurobindo Pharma’s Hyderabad facility

19 Apr 2017 Evaluate

The US Food and Drug Administration (USFDA) has issued Form 483 with 6 observations to Aurobindo Pharma’s Unit III, a formulation manufacturing facility located at Bachupally in Hyderabad.

The USFDA had conducted an inspection from April 10, 2017 to April 18, 2017. The observations are all on procedural improvements. None of the observations are related to data integrity. The company will be responding as per the prescribed time lines.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Aurobindo Pharma Share Price

1131.80 28.25 (2.56%)
26-Apr-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1504.25
Dr. Reddys Lab 6263.70
Cipla 1406.25
Zydus Lifesciences 948.20
Lupin 1615.85
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.